Abstract

Although severe atopic dermatitis (SAD) represent less than 20% of all patients with atopic dermatitis, in this subgroup of subjects quality of life is markedly disturbed. As real-world data concerning dupilumab in patients with SAD are currently scarce, we investigated the early effect of dupilumab in a selected SAD cohort in a real-world background.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call